The next quantum step forward in the treatment of Parkinson's disease will be the development of therapies which slow the progression of the disease. Testing of new agents will require recruitment of recently diagnosed Parkinson's disease subjects and retention of them in therapeutic trials lasting five to ten years. The extensive experience of the Oregon Health &Science University Parkinson Center of Oregon in conducting clinical trials, specifically long trials in recently diagnosed subjects, supports our inclusion in a cooperative multicenter trial of neruoprotective agents for Parkinson's disease. We also propose a number of means by which we may increase enrollment of de novo subjects, including subjects from minority groups, and retain them in the study. In addition, long-term trials of neuroprotective agents in early Parkinson's disease offer a unique opportunity to study the natural history of family care giving, assess caregiver strain as an outcome variable for new therapeutics and identify potential interventions to reduce care giving strain. These studies will extend and expand the preliminary studies of family care giving in Parkinson's disease we have done in the Parkinson Study Group DATATOP cohort.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10NS044483-10
Application #
8206528
Study Section
Special Emphasis Panel (ZNS1-SRB-L (01))
Program Officer
Moy, Claudia S
Project Start
2002-09-15
Project End
2012-11-30
Budget Start
2011-12-01
Budget End
2012-11-30
Support Year
10
Fiscal Year
2012
Total Cost
$86,521
Indirect Cost
$21,711
Name
Oregon Health and Science University
Department
Neurology
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239